CoChat
Sign Up
Cited by 521Advanced Glycation End Products researchAldose Reductase and TaurineChronic Kidney Disease and Diabetes

Receptor for AGE (RAGE): Signaling mechanisms in the pathogenesis of diabetes and its complications

Open access
Ramasamy, Ravichandran, Yan, Shi Fang, Schmidt, Ann Marie·2011·Annals of the New York Academy of Sciences
DOI 10.1111/j.1749-6632.2011.06320.xPMC PMC4501013
Open this paper in CoChat — free accountOpen PDF

Abstract

The receptor for advanced glycation endproducts (RAGE) was first described as a signal transduction receptor for advanced glycation endproducts (AGEs), the products of nonenzymatic glycation and oxidation of proteins and lipids that accumulate in diabetes and in inflammatory foci. The discovery that RAGE was a receptor for inflammatory S100/calgranulins and high mobility group box 1 (HMGB1) set the stage for linking RAGE to both the consequences and causes of types 1 and 2 diabetes. Recent discoveries regarding the structure of RAGE as well as novel intracellular binding partner interactions advance our understanding of the mechanisms by which RAGE evokes pathological consequences and underscore strategies by which antagonism of RAGE in the clinic may be realized. Finally, recent data tracking RAGE in the clinic suggest that levels of soluble RAGEs and polymorphisms in the gene encoding RAGE may hold promise for the identification of patients who are vulnerable to the complications of diabetes and/or are receptive to therapeutic interventions designed to prevent and reverse the damage inflicted by chronic hyperglycemia, irrespective of its etiology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1749-6632.2011.06320.x

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Activation of AGE-RAGE results in increased oxidative stress, inflammation and apoptosis in ischemia-reperfusion-induced myocardial injury in diabetic rats.

    “The activation of advanced glycation end products-receptor for advanced glycation end products (AGE-RAGE) results in increased oxidative stress, inflammation and apoptosis in ischemia-reperfusion (IR)-induced myocardial injury in diabetic rats (40).”

    From Mangiferin: An effective therapeutic agent against several disorders (Review) (2018) · cites this paper as [40]

    The animal-models section (page not provided) reports greater ischemia–reperfusion injury in diabetic mouse hearts and improvement with RAGE blockade or deletion. It also links RAGE to apoptosis and oxidative stress in isolated mouse cardiomyocytes, but does not report inflammation in the myocardial-injury experiments or findings in diabetic rats. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 97

  1. [1]Forlenza GP Paradise Black NM McNamara EG Sullivan SE Ankyloglossia, exclusive breastfeeding, and failure to thrive Pediatrics 2010 125 e1500 e1504 20498175
  2. [2]Peng H Hagopian W Environmental factors in the development of Type 1 diabetes Rev. Endocr. Metab. Disord 2006 7 149 162 17203405
  3. [5]Sweat V Bruzzese JM Albert S The Banishing Obesity and Diabetes in Youth (BODY) Project: description and feasibility of a program to halt obesity-associated disease among urban high school students J. Community Health 2011 In press 21826529
  4. [6]Kislinger T Fu C Huber B N (epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression J. Biol. Chem 1999 274 31740 31749 10531386
  5. [7]Hofmann MA Drury S Fu C RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides Cell 1999 97 889 901 10399917
  6. [9]Moss SE Klein R Klein BE Cause-specific mortality in a population-based study of diabetes Am. J. Public. Health 1991 81 1158 1162 1951827 PMC1405646
  7. [10]Nathan DM Cleary PA Backlund JY G. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N. Engl. J. Med 2005 353 2643 2653 16371630 PMC2637991
  8. [11]Khaw KT Wareham N Bingham S Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk Ann. Intern. Med 2004 141 413 420 15381514
  9. [12]Action to Control Cardiovascular Risk in Diabetes Study Group Gerstein HC Miller ME Byington RP Effects of intensive glucose lowering in type 2 diabetes N. Engl. J. Med 2008 358 2545 2559 18539917 PMC4551392
  10. [17]Cipollone F Iezzi A Fazia M The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control Circulation 2003 108 1070 1077 12912808
  11. [18]Park L Raman KG Lee KJ Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts Nat. Med 1998 4 1025 1031 9734395
  12. [19]Bucciarelli LG Wendt T Qu W RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice Circulation 2002 106 2827 2835 12451010
  13. [20]Wendt T Harja E Bucciarelli L RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes Atherosclerosis 2006 185 70 77 16076470
  14. [21]Harja E Bu DX Hudson BI Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE−/−mice J. Clin. Invest 2008 118 183 194 18079965 PMC2129235
  15. [22]Soro-Paavonen A Watson AM Li J Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes Diabetes 2008 57 2461 2469 18511846 PMC2518498
  16. [23]Sun L Ishida T Yasuda T RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in nondiabetic LDL receptor-deficient mice Cardiovasc. Res 2009 82 371 381 19176597
  17. [24]Bu DX Rai V Shen X Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice Circ. Res 2010 106 1040 1051 20133903 PMC2848909
  18. [25]Morris-Rosenfeld S Blessing E Preusch MR Deletion of bone marrow-derived receptor for advanced glycation end products inhibits atherosclerotic plaque progression Eur. J. Clin. Invest 2011 41 1164 1171 21418204
  19. [26]Bucciarelli LG Ananthakrishnan R Hwang YC RAGE and modulation of ischemic injury in the diabetic myocardium Diabetes 2008 57 1941 1951 18420491 PMC2453611
  20. [28]Wang LJ Lu L Zhang FR Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and nondiabetic patients with heart failure Eur. J. Heart Fail 2011 13 440 449 21266376
  21. [29]Ma H Li SY Xu P Advanced glycation end-product (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy J. Cell. Mol. Med 2009 13 1751 1764 19602045 PMC2829341
  22. [30]Nielsen JM Kristiansen SB Nørregaard R Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice Eur. J. Heart Fail 2009 11 638 647 19502378
  23. [31]Petrova R Yamamoto Y Muraki K Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes J. Mol. Cell. Cardiol 2002 34 1425 1431 12393002
  24. [32]Aleshin A Ananthakrishnan R Li Q RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model Am. J. Physiol. Heart Circ. Physiol 2008 294 H1823 H1832 18245563
  25. [33]Andrassy M Volz HC Igwe JC High-mobility group box-1 in ischemia-reperfusion injury of the heart Circulation 2008 117 3216 3226 18574060
  26. [34]Falcone C Emanuele E D’Angelo A Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men Arterioscler. Thromb. Vasc. Biol 2005 25 1032 1037 15731496
  27. [35]Colhoun HM Betteridge DJ Durrington P Total soluble and endogenous secretory receptor for advanced glycation endproducts as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial Diabetes 2011 60 2379 2385 21771973 PMC3161327
  28. [36]Tam HL Shiu SW Wong Y Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes Atherosclerosis 2010 209 173 177 19733353
  29. [37]Santilli F Bucciarelli L Noto D Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins Free Radic. Biol. Med 2007 43 1255 1262 17893038
  30. [38]Wilson C Cardiovascular endocrinology: RAGE-a biomarker for CHD in T2DM? Nat. Rev. Endocrinol 2011 7 561 21826104
  31. [39]Kalousovaá M Hodkovaá M Kazderovaá M Soluble receptor for advanced glycation end products in patients with decreased renal function Am. J. Kidney Dis 2006 47 406 411 16490618
  32. [40]Cuccurullo C Iezzi A Fazia ML Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes Arterioscler. Thromb. Vasc. Biol 2006 26 2716 2723 17038636
  33. [41]Liang YJ Chen SA Jian JH Peroxisome proliferator-activated receptor delta downregulates the expression of the receptor for advanced glycation end products and pro-inflammatory cytokines in the kidney of streptozotocin-induced diabetic mice Eur. J. Pharm. Sci 2011 43 65 70 21458563
  34. [42]Ishibashi Y Nishino Y Matsui T Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level Metabolism 2011 60 1271 1277 21388644
  35. [43]Wang L Zhang X Liu L Atorvastatin protects rat brains against permanent focal ischemia and down-regulates HMGB1, HMGB1 receptors (RAGE and TLR4), NF-kappaB expression Neurosci. Lett 2010 471 152 156 20100543
  36. [44]Ritz E Orth SR Nephropathy in patients with type 2 diabetes mellitus N. Engl. J. Med 1999 341 1127 1133 10511612
  37. [46]Bolton WK Cattran DC Williams ME Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy Am. J. Nephrol 2004 24 32 40 14685005
  38. [47]Tanji N Markowitz GS Fu C Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease J. Am. Soc. Nephrol 2000 11 1656 1666 10966490
  39. [48]Wendt TM Tanji N Guo J RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy Am. J. Pathol 2003 162 1123 1137 12651605 PMC1851245
  40. [49]Jensen LJ Denner L Schrijvers BF Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice J. Endocrinol 2006 188 493 501 16522729
  41. [50]Flyvbjerg A Denner L Schrijvers BF Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice Diabetes 2004 53 166 172 14693711
  42. [51]Reiniger N Lau K McCalla D Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse Diabetes 2010 59 2043 2054 20627935 PMC2911065
  43. [52]Chung AC Zhang H Kong YZ Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling J. Am. Soc. Nephrol 2010 21 249 260 19959709 PMC2834552
  44. [53]Ruüster C Franke S Wenzel U Podocytes of AT2 receptor knockout mice are protected from angiotensin II-mediated RAGE induction Am. J. Nephrol 2011 34 309 317 21846974
  45. [54]Li J Schmidt AM Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products J. Biol. Chem 1997 272 16498 16506 9195959
  46. [56]Chang JS Wendt T Qu W Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products Circ. Res 2008 102 905 913 18323529
  47. [57]Bierhaus A Schiekofer S Schwaninger M Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB Diabetes 2001 50 2792 2808 11723063
  48. [58]Kislinger T Tanji N Wendt T Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice Arterioscler. Thromb. Vasc. Biol 2001 21 905 910 11397695
  49. [59]Christaki E Opal SM Keith JC Jr. A monoclonal antibody against RAGE alters gene expression and is protective in experimental models of sepsis and pneumococcal pneumonia Shock 2011 35 492 498 21263385
  50. [60]van Zoelen MA van der Sluijs KF Achouiti A Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia Virology 2009 391 265 273 19592063 PMC4540231
  51. [61]van Zoelen MA Schouten M de Vos AF The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia J. Immunol 2009 182 4349 4356 19299735
  52. [62]Ramsgaard L Englert JM Manni ML Lack of the receptor for advanced glycation end-products attenuates E. coli pneumonia in mice PLoS One 2011 6 e20132 21629785 PMC3100338
  53. [63]Lutterloh EC Opal SM Pittman DD Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection Crit. Care 2007 11 R122 18042296 PMC2246216
  54. [64]Schmidt AM Weidman E Lalla E Advanced glycation endproducts (AGEs) induce oxidant stress in the gingiva: a potential mechanism underlying accelerated periodontal disease associated with diabetes J. Periodont. Res 1996 31 508 515 8915955
  55. [65]Lalla E Lamster IB Feit M Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice J. Clin. Invest 2000 105 1117 1124 10772656 PMC300834
  56. [66]Pollreisz A Hudson BI Chang JS Receptor for advanced glycation endproducts mediates proatherogenic responses to periodontal infection in vascular endothelial cells Atherosclerosis 2010 212 451 456 20701913 PMC2952730
  57. [67]Riehl A Bauer T Brors B Identification of the Rage-dependent gene regulatory network in a mouse model of skin inflammation BMC Genom 2010 11 537 PMC3091686 20923549
  58. [68]Gao J Shao Y Lai W Association of polymorphisms in the RAGE gene with serum CRP levels and coronary artery disease in the Chinese Han population J. Hum. Genet 2010 55 668 675 20668462
  59. [69]Chen Y Yan SS Colgan J Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products J. Immunol 2004 173 1399 1405 15240736
  60. [70]Moser B Szabolcs MJ Ankersmit HJ Blockade of RAGE suppresses alloimmune reactions in vitro and delays allograft rejection in murine heart transplantation Am. J. Transplant 2007 7 293 302 Erratum in Am. J. Transplant. 2007 May; 2007(2005): 1318 17241110
  61. [71]Moser B Desai DD Downie MP Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo J. Immunol 2007 179 8051 8058 18056345
  62. [72]Lee BW Chae HY Kwon SJ RAGE ligands induce apoptotic cell death of pancreatic beta-cells via oxidative stress Int. J. Mol. Med 2010 26 813 818 21042774
  63. [73]Zhu Y Shu T Lin Y Inhibition of the receptor for advanced glycation endproducts (RAGE) protects pancreatic beta-cells Biochem. Biophys. Res. Commun 2011 404 159 165 21111711
  64. [74]Shu T Zhu Y Wang H AGEs decrease insulin synthesis in pancreatic beta-cell by repressing Pdx-1 protein expression at the post-translational level PLoS One 2011 6 e18782 21533167 PMC3078922
  65. [75]Neeper M Schmidt AM Brett J Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins J. Biol. Chem 1992 267 14998 15004 1378843
  66. [76]Leclerc E Fritz G Vetter SW Heizmann CW Binding of S100 proteins to RAGE: an update Biochim. Biophys. Acta 2009 1793 993 1007 19121341
  67. [77]Koch M Chitayat S Dattilo BM Structural basis for ligand recognition and activation of RAGE Structure 2010 18 1342 1352 20947022 PMC4250094
  68. [78]Park H Adsit FG Boyington JC The 1.5 A~ crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding J. Biol. Chem 2010 285 40762 40770 20943659 PMC3003376
  69. [79]Xue J Rai V Singer D Advanced glycation end product recognition by the receptor for AGEs Structure 2011 19 722 732 21565706 PMC3150472
  70. [80]Sarkany Z Ikonen T Ferreira-da-Silva F Solution structure of the soluble receptor for advanced glycation end-products (sRAGE) J. Biol. Chem 2011 286 37,525 37,534 PMC3199498 21865159
  71. [81]Huttunen HJ Fages C Rauvala H Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways J. Biol. Chem 1999 274 19919 19924 10391939
  72. [83]Huang JS Guh JY Chen HC Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells J. Cell. Biochem 2001 81 102 113 11180401
  73. [84]Yeh CH Sturgis L Haidacher J Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion Diabetes 2001 50 1495 1504 11375353
  74. [85]Schmidt AM Vianna M Gerlach M Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface J. Biol. Chem 1992 267 14987 14997 1321822
  75. [86]Hudson BI Kalea AZ Del Mar Arriero M Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42 J. Biol. Chem 2008 283 34457 34468 18922799 PMC2590709
  76. [87]Krebs A Rothkegel M Klar M Jockusch BM Characterization of functional domains of mDia1, a link between the small GTPase Rho and the actin cytoskeleton J. Cell. Sci 2001 114 3663 3672 11707518
  77. [88]Tominaga T Sahai E Chardin P Diaphanous-related formins bridge Rho GTPase and Src tyrosine kinase signaling Mol. Cell 2000 5 13 25 10678165
  78. [89]Sakaguchi M Murata H Yamamoto K TIRAP, an adaptor protein for TLR2/4, transduces a signal from RAGE phosphorylated upon ligand binding PLoS One 2011 6 e23132 21829704 PMC3148248
  79. [90]Young KG Copeland JW Formins in cell signaling Biochim. Biophys. Acta 2010 1803 183 190 18977250
  80. [91]Geneste O Copeland JW Treisman R LIM kinase and Diaphanous cooperate to regulate serum response factor and actin dynamics J. Cell Biol 2002 157 831 838 12034774 PMC2173419
  81. [92]Copeland JW Treisman R The diaphanous-related formin mDia1 controls serum response factor activity through its effects on actin polymerization Mol. Biol. Cell 2002 13 4088 4099 12429848 PMC133616
  82. [93]Xu Y Toure F Qu W Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages J. Biol. Chem 2010 285 23233 23240 20507991 PMC2906316
  83. [94]Balasubbu S Sundaresan P Rajendran A Association analysis of nine candidate gene polymorphisms in Indian patients with type 2 diabetic retinopathy BMC Med. Genet 2010 11 158 21067572 PMC2994838
  84. [95]Zong H Ward M Madden A Hyperglycaemia-induced pro-inflammatory responses by retinal Muller glia are regulated by the receptor for advanced glycation end-products (RAGE) Diabetologia 2010 53 2656 2666 20835858
  85. [96]Zhang HM Chen LL Wang L Association of 1704G/T and G82S polymorphisms in the receptor for advanced glycation end products gene with diabetic retinopathy in Chinese population J. Endocrinol. Invest 2009 32 258 262 19542745
  86. [97]Barile GR Schmidt AM RAGE and its ligands in retinal disease Curr. Mol. Med 2007 7 758 765 18331234
  87. [98]Kaji Y Usui T Ishida S Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products Invest. Ophthalmol. Vis. Sci 2007 48 858 865 17251488
  88. [99]Pachydaki SI Tari SR Lee SE Upregulation of RAGE and its ligands in proliferative retinal disease Exp. Eye Res 2006 82 807 815 16364297
  89. [100]Barile GR Pachydaki SI Tari SR The RAGE axis in early diabetic retinopathy Invest. Ophthalmol. Vis. Sci 2005 46 2916 2924 16043866
  90. [101]Brussee V Guo G Dong Y Distal degenerative sensory neuropathy in a long-term type 2 diabetes rat model Diabetes 2008 57 1664 1673 18332094
  91. [102]Toth C Rong LL Yang C Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy Diabetes 2008 57 1002 1017 18039814
  92. [103]Haslbeck KM Schleicher E Bierhaus A The AGE/RAGE/NF-(kappa)B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT) Exp. Clin. Endocrinol. Diabetes 2005 113 288 291 15926115
  93. [104]Bierhaus A Haslbeck KM Humpert PM Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily J. Clin. Invest 2004 114 1741 1751 15599399 PMC535062
  94. [105]Berlanga J Cibrian D Guillen I Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds Clin. Sci 2005 109 83 95 15755259
  95. [106]Wear-Maggitti K Lee J Conejero A Use of topical sRAGE in diabetic wounds increases neovascularization and granulation tissue formation Ann. Plast. Surg 2004 52 519 521 Discussion 522 15096944
  96. [107]Santana RB Xu L Chase HB A role for advanced glycation end products in diminished bone healing in type 1 diabetes Diabetes 2003 52 1502 1510 12765963
  97. [108]Goova MT Li J Kislinger T Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice Am. J. Pathol 2001 159 513 525 11485910 PMC1850533

Cited by

Sorted by citations

Authors
Ramasamy, R., Yan, S. F., & Schmidt, A. M.
Affiliations
New York University (US)
Corresponding author
Schmidt, Ann Marie
ORCID
Venue
Annals of the New York Academy of Sciences
Publisher
Wiley
Published
2011-12
Volume
1243
Issue
1
Pages
88-102
ISSN
  • 0077-8923 (ISSN-L)
  • 1749-6632
DOI
10.1111/j.1749-6632.2011.06320.x
PMC
PMC4501013
OpenAlex
W1598235393
Cited by
521
References
10
Citations by year
2026: 30 · 2025: 41 · 2024: 47 · 2023: 45 · 2022: 38 · 2021: 37 · 2020: 38 · 2019: 28 · 2018: 29 · 2017: 30 · 2016: 25 · 2015: 35 · 2014: 32 · 2013: 41 · 2012: 22
FWCI
3.62
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 22 d)
Locations
  • Annals of the New York Academy of Sciences (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute on Aging (P01AG026467)
  • National Heart, Lung, and Blood Institute (P01HL060901)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Aldose Reductase and Taurine
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
receptor for advanced glycation end products, RAGE, advanced glycation end products, diabetes pathogenesis, diabetes complications, S100/calgranulins, HMGB1, RAGE signaling, soluble RAGE, RAGE gene polymorphisms, chronic hyperglycemia, inflammation
MeSH terms
Receptor for Advanced Glycation End Products, Formins, Animals, Cardiovascular Diseases, Carrier Proteins, Diabetes Mellitus, Diabetic Nephropathies, Humans, Inflammation, Receptors, Immunologic, Signal Transduction, Diabetes Complications, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review